Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ALXN210
ALXN210
FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria
CP Wire
Mon, 08/20/18 - 11:40 am
Alexion Pharmaceuticals
Alexion
FDA
ALXN210
PNH
paroxysmal nocturnal hemoglobinuria
